13F Pro quality score
Rank #2,846 of 2,884
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Jaguar Health, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $11.5M | $-53.6M | — |
| FY 2024 | 10-K | $11.7M | $-39.3K | — |
| FY 2023 | 10-K | $9.8M | $-41.9K | — |
| FY 2022 | 10-K | $12.0M | $-48.4K | — |
| FY 2021 | 10-K | $4.3M | $-52.6K | — |
| FY 2020 | 10-K | $9.4M | $-33.8M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Jaguar Health, Inc. (JAGX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JAGX at 12.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,846 of 2,884 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (1.4) and balance sheet strength (2.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Jaguar Health, Inc. reports quarterly revenue of $1.2M, net income of $-12.8M. Top institutional holders of JAGX by reported 13-F value include UBS Group AG, Tower Research Capital (TRC), SBI Securities , Ltd., based on the most recent SEC filings. JAGX trades on the Nasdaq exchange and files with the SEC under CIK 1585608. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JAGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jaguar Health, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1585608 →